PAOG U.S. Patent Backed CBD Pharmaceutical Development Remains On Track
April 08 2021 - 8:57AM
InvestorsHub NewsWire
Sandusky, OH --
April 8, 2021 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today announced a management update on the company’s
ongoing CBD Pharmaceutical Development Program progress scheduled
to be released next week on Tuesday, April 13,
2021.
Last year,
PAOG acquired
RespRx from Kali-Extracts, Inc. (OTC
Pink: KALY). RespRx is a CBD treatment under development for
Chronic Obstructive Pulmonary Disorder (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS
PLANT."
PAOG is working
with Veristat, a contract research organization (CRO),
dedicated to the clinical advance of therapies and treatments
through regulatory approval. PAOG anticipates soon
announcing new breakthroughs in its CBD RespRx pharmaceutical
research.
Last month, PAOG
released a comprehensive update on its CBD
Nutraceutical Development Program with the first PAOG CBD
Nutraceutical products, packaged by Alkame Holdings, Inc. (USOTC:
ALKM), expected to come to market before the end of this year
marketed through North American Cannabis Holdings, Inc. (USOTC:
USMJ). Next week, on Tuesday, PAOG will release a similar
update on its CBD Pharmaceutical Development
Program,
Learn more about
PAOG at www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Oct 2023 to Oct 2024